financetom
Business
financetom
/
Business
/
B&G Foods Q2 adjusted profit misses estimates, cuts FY guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
B&G Foods Q2 adjusted profit misses estimates, cuts FY guidance
Aug 4, 2025 1:42 PM

Overview

* B&G Foods Q2 2025 net sales fell 4.5%, missing analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 missed estimates

* Co revised full-year guidance downward for net sales, adjusted EBITDA, and adjusted EPS

Outlook

* B&G Foods ( BGS ) revises 2025 net sales guidance to $1.83 bln-$1.88 bln

* Company expects 2025 adjusted EBITDA between $273 mln and $283 mln

* B&G Foods ( BGS ) sees 2025 adjusted EPS at $0.50-$0.60

* Company says guidance excludes potential tariff impacts

Result Drivers

* VOLUME DECLINE - Co attributes decrease in net sales to reduced volume, impacting base business net sales by $14.3 mln

* PRICING PRESSURE - Lower net pricing and unfavorable product mix contributed to a $4.0 mln reduction in base business net sales

* CURRENCY IMPACT - Foreign currency negatively affected net sales by $0.4 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Miss $424.40 $427.90

mln mln (4

Analysts

)

Q2 Miss $0.04 $0.06 (5

Adjusted Analysts

EPS )

Q2 EPS -$0.12

Q2 Miss $2.90 $5.85

Adjusted mln mln (2

Net Analysts

Income )

Q2 Miss $58 mln $62 mln

Adjusted (4

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the food processing peer group is "buy."

* Wall Street's median 12-month price target for B&G Foods Inc ( BGS ) is $5.50, about 24.7% above its August 1 closing price of $4.14

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Itron Insider Sold Shares Worth $3,930,998, According to a Recent SEC Filing
Itron Insider Sold Shares Worth $3,930,998, According to a Recent SEC Filing
Oct 3, 2024
12:30 PM EDT, 10/03/2024 (MT Newswires) -- Thomas Deitrich, Director, President & CEO, on October 01, 2024, sold 37,500 shares in Itron ( ITRI ) for $3,930,998. Following the Form 4 filing with the SEC, Deitrich has control over a total of 230,276 shares of the company, with 205,276 shares held directly and 25,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/780571/000112760224025027/xslF345X05/form4.xml Price:...
--Blue Owl Capital in Talks to Acquire IPI Partners for $1 Billion, Bloomberg Reports
--Blue Owl Capital in Talks to Acquire IPI Partners for $1 Billion, Bloomberg Reports
Oct 3, 2024
12:30 PM EDT, 10/03/2024 (MT Newswires) -- Price: 19.90, Change: +0.20, Percent Change: +1.02 ...
Market Chatter: Helix Energy Mulls Strategic Options, Including Sale
Market Chatter: Helix Energy Mulls Strategic Options, Including Sale
Oct 3, 2024
12:32 PM EDT, 10/03/2024 (MT Newswires) -- Helix Energy (HLX) is considering various strategic options, including the possibility of a sale, Bloomberg reported Thursday, citing people familiar with the matter. The company is working with advisers to gauge potential buyer interest, according to the people. Discussions are reportedly still in early stages and there is no certainty that Helix Energy...
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
Oct 3, 2024
12:37 PM EDT, 10/03/2024 (MT Newswires) -- Eli Lilly ( LLY ) , CVS's (CVS) pharmacy unit and other drug companies and pharmacy benefit managers have been sued by Texas Attorney General Ken Paxton for allegedly inflating insulin prices, Paxton's office said Thursday. Paxton accused the major insulin manufacturers of artificially and willingly raising prices and then paying pharmacy benefit...
Copyright 2023-2026 - www.financetom.com All Rights Reserved